Appili Therapeutics (OTCMKTS:APLIF – Get Free Report) posted its quarterly earnings data on Friday. The company reported $999.00 earnings per share (EPS) for the quarter, Zacks reports.
Appili Therapeutics Price Performance
OTCMKTS:APLIF opened at $0.01 on Friday. The firm’s 50-day moving average price is $0.01 and its 200-day moving average price is $0.01. The company has a market capitalization of $1.50 million, a PE ratio of -0.38 and a beta of -0.06. Appili Therapeutics has a 1-year low of $0.01 and a 1-year high of $0.03.
Appili Therapeutics Company Profile
Appili Therapeutics Inc is a clinical-stage pharmaceutical company headquartered in Vancouver, Canada. The company specializes in the development and commercialization of novel anti-infective therapies designed to address both endemic and emerging infectious disease threats. Appili’s strategic focus includes small-molecule antibiotics, antivirals and vaccine adjuvants, with an emphasis on formulations suitable for rapid deployment in resource-limited or outbreak settings.
Appili’s product pipeline features multiple candidates in various stages of development.
Recommended Stories
- Five stocks we like better than Appili Therapeutics
- SpaceX Has Real Value—But These 3 Stocks Have Better Odds Right Now
- 3 Stocks That Could Benefit as the Robotaxi Race Heats Up
- 3 Waste Stocks Turning AI Investments into Growth
- 3 Overlooked Tech ETFs That Are Quietly Killing It This Year
Receive News & Ratings for Appili Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Appili Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
